Breaking Finance News

Elekta AB (ADR) (OTC:EKTAY) has been downgraded from Overweight to Neutral in a statement by JP Morgan earlier today.

Boasting a price of $8.36, Elekta AB (ADR) (OTC:EKTAY) traded 2.17% higher on the day. With the last close down 0.49% from the two hundred day average, compared with the S&P 500 Index which has increased 0.02% over the date range. Elekta AB (ADR) has recorded a 50-day average of $10.35 and a two hundred day average of $9.84. Volume of trade was down over the average, with 985 shares of EKTAY changing hands under the typical 5,759

JP Morgan has downgraded Elekta AB (ADR) (OTC:EKTAY) from Overweight to Neutral in a statement released on 11/13/2017.

Performance Chart


With a total market value of $0, Elekta AB (ADR) has price-earnings ratio of 159.52 with a one year low of $7.97 and a one year high of $11.18 .

More About Elekta AB (ADR) (OTC:EKTAY)

Elekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies. Its neuroscience solutions comprise Gamma Knife radiosurgery for the treatment of brain disorders; stereotactic neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform. The company also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system; Elekta Axesse, a stereotactic radiation therapy system; Elekta Compact, a gateway to RT for oncology centers; Elekta Synergy system that visualizes tumor targets and normal tissue, and their movement between and during fractions; treatment planning systems; oncology information systems solutions; Versa HD, a linear accelerator; and Elekta Infinity system for volumetric arc modulated therapy, as well as various treatment techniques. In addition, it offers brachytherapy solutions that include afterloading platforms; real-time prostate solutions; Oncentra Brachy, a radiotherapy treatment planning system; Esteya for treating skin cancer; and applicators. Further, the company provides software products, including MOSAIQ oncology information system; Oncology Informatics/Data Alliances that streamlines the flow of information in the cancer care team; medical oncology software; Clarity Soft Tissue Visualization, a software for radiation therapy; Monaco, a treatment planning system; Venezia, an applicator for treating gynecological cancer; and METRIQ, a cancer registry data solution. It also offers installation, implementation, training, education, and consultative services. It primarily serves hospitals and academic institutions. The company was founded in 1972 and is headquartered in Stockholm, Sweden.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.